Loading clinical trials...
Loading clinical trials...
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors: A Prospective, Single-Arm Clinical Study
Conditions
Interventions
Sup19 CAR-T
Locations
1
China
Institute of Hematology, Chinese Academy of Medical Sciences & Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Start Date
April 1, 2026
Primary Completion Date
November 1, 2027
Completion Date
November 1, 2027
Last Updated
April 20, 2026
NCT07239323
NCT07106749
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions